Bayer’s Finerenone Marches Forward, But Is Phase III Design Too Steep A Hill?
This article was originally published in The Pink Sheet Daily
Executive Summary
Heart failure drug's safety profile should become more clear – if the two-indication program hits the mark on dose selection and the evolving standard of care.